This book is not intended as a full detailed report on hypertension and related disorders, but instead focuses on particular issues in hypertension. It looks at emerging recently described forms of hypertension that are frequently encountered in clinical practice (prehypertension, white-coat and masked hypertension, hypertension in the elderly) and discusses novel aspects of target organ disease (for example, cognitive impairment, dementia, and sexual dysfunction), and changing concepts in the management of hypertension and antihypertensive pharmacotherapy. It also looks at specific topics…mehr
This book is not intended as a full detailed report on hypertension and related disorders, but instead focuses on particular issues in hypertension. It looks at emerging recently described forms of hypertension that are frequently encountered in clinical practice (prehypertension, white-coat and masked hypertension, hypertension in the elderly) and discusses novel aspects of target organ disease (for example, cognitive impairment, dementia, and sexual dysfunction), and changing concepts in the management of hypertension and antihypertensive pharmacotherapy. It also looks at specific topics that are rarely discussed in books, including hypertension control in postmenopausal women on hormonal replacement therapy, Ramadan fasting, painful inflammatory disorders, and aldosterone escape. Finally, it examines newer cardiovascular risk factors (for example, uric acid, circadian blood pressure changes, blood pressure variability).
1 Prehypertension: Definition, clinical significance and therapeutic approaches: to treat or not to treat.- 2 Clinical significance and treatment requirement in white coat and masked hypertension.- 3 Resistant hypertension: epidemiologic and evolving therapeutic aspects.- 4 Primary aldosteronism: rare or common condition.- 5 Hypertension in the very elderly: special features, therapeutic approaches and problems.- 6 Clinical relevance of circadian rhythm and nocturnal dip.- 7 Morning BP surge in treated and untreated hypertensive patients: clinical relevance, prognostic significance and therapeutic approaches.- 8 Short-term and long-term BP variability.- 9 Home BP in hypertension.- 10 Obstructive sleep apnea.- 11 Hypertension, obesity and the metabolic syndrome.- 12 Salt, hypertension and cardiovascular disease.- 13 Optic fundus and retinal circulation: new technology for an old examination.- 14 Arterial stiffness as an early marker of organ damage.- 15 Central blood pressure: definition, clinical significance and therapeutic approaches.- 16 Assessment of total cardiovascular risk in Hypertension: the role of subclinical organ damage.- 17 Microcirculation in hypertension.- 18 Smoking, nicotine and BP.- 19 Inflammatory markers and other risk factors in Hypertension.- 20 Benefits: pleiotropic versus BP dependent mechanisms.- 21 Threshold and target BP values for treatment: an evolving concept.- 22 Polypill concept.- 23 J-curve phenomenon: Does it exist?.- 24 Residual risk in treated hypertension.- 25 Poor BP control in the hypertensive population: which factors are involved.- 26 Ramadan fasting and BP control.- 27 Hormone replacement therapy in postmenopausal hypertensive women.- 28 Treating pain and inflammation in hypertension.- 29 Sexual function in untreated and treated hypertension.- 30 Cognitive function and dementia in hypertension. Epidemiologic and therapeutic aspects.- 31 Is hypertension preventable?.- 32 Atrial fibrillation. Modern epidemiologic and therapeutic aspects.- 33 Genetics and hypertension. Which information for clinical practice.- 34 Dual blockade of RAAS: benefits versus adverse Outcome.- 35 Long-term effects of RAAS blockade on renal function.
1 Prehypertension: Definition, clinical significance and therapeutic approaches: to treat or not to treat.- 2 Clinical significance and treatment requirement in white coat and masked hypertension.- 3 Resistant hypertension: epidemiologic and evolving therapeutic aspects.- 4 Primary aldosteronism: rare or common condition.- 5 Hypertension in the very elderly: special features, therapeutic approaches and problems.- 6 Clinical relevance of circadian rhythm and nocturnal dip.- 7 Morning BP surge in treated and untreated hypertensive patients: clinical relevance, prognostic significance and therapeutic approaches.- 8 Short-term and long-term BP variability.- 9 Home BP in hypertension.- 10 Obstructive sleep apnea.- 11 Hypertension, obesity and the metabolic syndrome.- 12 Salt, hypertension and cardiovascular disease.- 13 Optic fundus and retinal circulation: new technology for an old examination.- 14 Arterial stiffness as an early marker of organ damage.- 15 Central blood pressure: definition, clinical significance and therapeutic approaches.- 16 Assessment of total cardiovascular risk in Hypertension: the role of subclinical organ damage.- 17 Microcirculation in hypertension.- 18 Smoking, nicotine and BP.- 19 Inflammatory markers and other risk factors in Hypertension.- 20 Benefits: pleiotropic versus BP dependent mechanisms.- 21 Threshold and target BP values for treatment: an evolving concept.- 22 Polypill concept.- 23 J-curve phenomenon: Does it exist?.- 24 Residual risk in treated hypertension.- 25 Poor BP control in the hypertensive population: which factors are involved.- 26 Ramadan fasting and BP control.- 27 Hormone replacement therapy in postmenopausal hypertensive women.- 28 Treating pain and inflammation in hypertension.- 29 Sexual function in untreated and treated hypertension.- 30 Cognitive function and dementia in hypertension. Epidemiologic and therapeutic aspects.- 31 Is hypertension preventable?.- 32 Atrial fibrillation. Modern epidemiologic and therapeutic aspects.- 33 Genetics and hypertension. Which information for clinical practice.- 34 Dual blockade of RAAS: benefits versus adverse Outcome.- 35 Long-term effects of RAAS blockade on renal function.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
